US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Patent 11116820 was granted and assigned to Eiger BioPharmaceuticals on September, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+356 characters)
Article
Patent abstract
In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Xiaofeng Xiong0
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111168200
Date of Patent
September 14, 2021
0Patent Application Number
202004170
Date Filed
April 17, 2020
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 18 Sep, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11116820
Date of patent
September 14, 2021
Patent application number
20200417
Date Filed
April 17, 2020
Find more entities like US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
